NCT04322292已完成1 期
A Phase Ⅰ Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2019年9月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Safety: The incidence of treatment-emergent adverse events (TEAEs)
研究概览
简要总结
This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.
详细描述
The study will include the following sequential phases: Screening, Pre- Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), C-CAR088 infusion and Follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-75 years old, male or female;
- •The patient volunteered to participate in the study, and he or his legal guardian signed the Informed Consent;
- •Meet the internationally accepted Criteria for the diagnosis of multiple myeloma (IMWG diagnostic criteria 2014);
- •Patients with a clear diagnosis of relapsed or refractory multiple myeloma；
- •The patient have one or more measurable multiple myeloma lesion, must include one of the following conditions:
- •Serum M protein≥1.0 g/dL(10g/L)
- •Urine M protein≥200 mg/24h
- •Serum free light chain(sFLC): κ/λ FLC ratio is abnormal and affected FLC ≥10mg / dL
- •Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological examination;
- •ECOG scores 0 - 1;
- •Echocardiography showed normal diastolic function, left ventricular ejection fraction (LVEF) ≥50%, and no severe arrhythmia;
- •No active pulmonary infections, normal pulmonary function and oxygen saturation ≥ 92% on room air.
- •Absolute neutrophil count ≥1.0 × 109 / L, platelet count ≥50 × 109 / L; total serum bilirubin ≤1.5mg / dl; serum ALT or AST less than 2.5 times the upper limit of normal; serum creatinine ≤2.0mg / dl;
- •No contraindications of peripheral blood apheresis;
- •Expected survival time > 12 weeks;.
- •Female subjects of childbearing age must have a negative urine / blood pregnancy test within 7 days before cell therapy and not be in lactation; female or male subjects of childbearing age need to take effective contraception throughout the study.
排除标准
- •Have a history of allergy to cellular products;
- •Presence of clinically significant cardiovascular disease;
- •A history of craniocerebral trauma, consciousness disorder, epilepsy, severe cerebral ischemia or hemorrhagic disease;
- •Need to use any anticoagulant (except aspirin);
- •Patients requiring urgent treatment due to tumor progression or spinal cord compression;
- •Patients with CNS metastasis or symptoms of CNS involvement;
- •After allogeneic hematopoietic stem cell transplantation;
- •Plasma cell leukemia;
- •Received systemic anti-tumor treatment within 2 weeks before apheresis, and within 1 week before apheresis, prednisone (or equivalent amount of other corticosteroids) was applied in excess of 5 mg/d ;
- •Patients with autoimmune diseases, immunodeficiency, or other immunosuppressive agents;
- •Uncontrolled active infection;
- •Have used any CAR T cell products or other genetically modified T cell therapy before;
- •Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as acquired, congenital immune deficiency diseases, including but not limited to HIV infected persons;
- •Have a history of alcoholism, drug addiction and mental illness;
- •Participated in any other clinical trial within 1 months;
- •The investigators believe that there are other circumstances that are not suitable for the trial.
研究组 & 干预措施
C-CAR088
Experimental
Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene.
干预措施: C-CAR088 (Drug)
结局指标
主要结局
Safety: The incidence of treatment-emergent adverse events (TEAEs)
时间窗: 30 days
The incidence of treatment-emergent adverse events (TEAEs)
次要结局
- Overall response rate (ORR)(12 months)
- Progression free survival (PFS)(6 months、12 months)
- The soluble BCMA changes in peripheral blood(12 months)
- The CART cell duration in vivo(12 months)
研究者
AnGang
Deputy Chief Physician
Institute of Hematology & Blood Diseases Hospital, China
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT03815383The First Affiliated Hospital with Nanjing Medical University12
招募中
1 期
Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid TumorsProtein Kinase InhibitorsOther Protocol Specified CriteriaLung NeoplasmsBrain NeoplasmsNCT06128148Guangzhou JOYO Pharma Co., Ltd101
终止
1 期
The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid TumorsSolid TumorColorectal CancerNCT04696848Tae Won Kim25
招募中
1 期
NV-001 in the Treatment of Advanced Solid TumorsMalignant NeoplasmNCT06051760Cancer Institute and Hospital, Chinese Academy of Medical Sciences20
已完成
1 期
A Single-dose Study of Octreotide Injection in Healthy Adult SubjectsAcromegalyNCT05761431CSPC ZhongQi Pharmaceutical Technology Co., Ltd.56